Eli Lilly struck a preclinical acquisition to strengthen non-viral DNA delivery for genetic medicines. Lilly will buy Engage Biologics for up to $202 million, using Engage’s Tethosome platform—a delivery approach that combines engineered DNA payloads with lipid nanoparticles and an mRNA-encoded protein designed to transport material to the cell nucleus.